Acadia Upgraded To Buy From Neutral At Goldman Sachs

March 31, 2020 at 06:54 AM EDT

Goldman Sachs analyst Salveen Richter upgraded Acadia Pharmaceuticals to Buy from Neutral with a price target of $72, up from $45.